Clinical Trial Update: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 multicenter study evaluating usability and safety of the SB5 pre-filled pen and syringe in rheumatoid arthritis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SB5 (adalimumab biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-04-01